Jiangsu Hengrui Pharmaceuticals (600276.SH): Fosrolapitant Palonosetron for Injection Approved for Additional Indication

date
17:05 19/11/2026
avatar
GMT Eight
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. recently received a notice from the National Medical Products Administration approving an additional indication for Fosrolapitant Palonosetron for Injection, the company's independently developed Class 1 innovative drug and China's first ultra-long-acting original dual-target antiemetic injection. The approved indication is "for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy (MEC) in adult patients."
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received a notice from the National Medical Products Administration approving an additional indication for fosrolapitant palonosetron for injection, the company's independently developed Class 1 innovative drug and China's first ultra-long-acting original dual-target antiemetic injection. The approved indication is "for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy (MEC) in adult patients."